Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, HC Wainwright Analyst Says

Key Points

• HC Wainwright raised its price target on Xenon from $53 to $74 and kept a "buy" rating, implying about a 17.9% upside; MarketBeat shows a consensus "Buy" rating with a $69.59 average target.
• Positive Phase‑3 X‑TOLE2 topline results for azetukalner showed a significant reduction in focal‑onset seizures and sparked heavy buying (the stock traded up ~49.6%), but Xenon also announced a proposed $500 million (plus $75 million option) public offering that could be dilutive.
• The shares trade near a 52‑week high (market cap ~$5.22B) after the rally, yet recent fundamentals include a quarterly EPS miss (‑$1.31) and a disclosed CEO sale of 40,000 shares, underscoring execution and insider dynamics investors should watch.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) had its price target raised by HC Wainwright from $53.00 to $74.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 17.91% from the stock's current price.

Several other equities analysts have also recently issued reports on the stock. Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Chardan Capital raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, November 19th. Robert W. Baird set a $97.00 price target on Xenon Pharmaceuticals and gave the stock an "outperform" rating in a research note on Monday. Jefferies Financial Group set a $100.00 price target on Xenon Pharmaceuticals in a research report on Monday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $69.59.

Xenon Pharmaceuticals Trading Up 49.6%

NASDAQ XENE opened at $62.76 on Tuesday. The stock has a market cap of $5.22 billion, a P/E ratio of -14.39 and a beta of 0.91. The company's fifty day simple moving average is $42.62 and its 200-day simple moving average is $41.41. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $62.91.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same period in the previous year, the business earned ($0.84) EPS. On average, research analysts expect that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $266,580. This trade represents a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.07% of the company's stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in XENE. Goldman Sachs Group Inc. boosted its holdings in Xenon Pharmaceuticals by 7.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company's stock valued at $14,854,000 after purchasing an additional 32,486 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Xenon Pharmaceuticals by 73.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 436,020 shares of the biopharmaceutical company's stock valued at $13,647,000 after purchasing an additional 184,873 shares in the last quarter. ProShare Advisors LLC acquired a new stake in Xenon Pharmaceuticals in the second quarter valued at approximately $577,000. Nan Fung Trinity HK Ltd. acquired a new position in Xenon Pharmaceuticals in the 2nd quarter worth about $4,964,000. Finally, Geode Capital Management LLC grew its holdings in shares of Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company's stock worth $30,369,000 after purchasing an additional 900,746 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Company-reported positive topline Phase 3 X-TOLE2 results for azetukalner showed a statistically significant reduction in focal-onset seizures, underpinning management’s plan to pursue regulatory filings and expanding commercial opportunity for a differentiated KV7 potassium-channel opener. GlobeNewswire: Positive Topline Data
• Positive Sentiment: Major media and wire services (Reuters, The Globe and Mail and others) highlighted the late‑stage success, increasing visibility and driving buying interest from momentum and fundamental investors. Reuters: Late‑stage trial met main goal
• Neutral Sentiment: Company hosted/discussed topline results in a call/transcript that provides additional trial detail, endpoints and next steps (useful for modelling approval timing, label and addressable market). Seeking Alpha: Transcript of results discussion
• Neutral Sentiment: Trading was temporarily halted prior to the announcement for “news pending,” a routine regulatory/market control that concentrated order flow at the release time and amplified the initial move. (No separate link available.)
• Negative Sentiment: Xenon concurrently announced a proposed underwritten public offering of $500 million (with a 30‑day option for an additional $75 million) of common shares — a potentially dilutive financing that could cap near‑term upside despite the positive clinical news. GlobeNewswire: Proposed public offering
• Negative Sentiment: Some analysts and commentaries caution the post‑data valuation may be rich and note market/commercial risks (crowded antiseizure market, adverse-event profile and execution risk), which could pressure the stock if expectations are not met. Seeking Alpha: Valuation caution

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.